The use of biologic therapies for the treatment of moderate-to-severe psoriasis in UK clinical practice

Richard B. Warren; Benjamin Brown; D. Lavery; Darren M. Ashcroft; Christopher Em Griffiths

Related publications

Article2008

Practical experience with biologic drug therapies for the treatment of psoriasis in a UK tertiary referral centre.

Benjamin Brown, Richard B. Warren, D. Lavery, Darren M. Ashcroft, Christopher Em Griffiths

Article2010

Comparing biological therapies in psoriasis: implications for clinical practice

Christopher Em Griffiths

Article2010

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Ulrich Mrowietz, Knud Kragballe, Kristian Reich, Phyllis I. Spuls, Christopher Em Griffiths, Alexander Nast, J Franke, C. Antoniou, Petr Arenberger, Flora Balieva, Matilda Bylaitė, Osvaldo Correia, E. Daudén, Paolo Gisondi, Lars Iversen, Lajos Kemény, M. Lahfa, Tamar Nijsten, Tapio Rantanen, Adam Reich, T. Rosenbach, Siegfried Segaert, Catherine Smith, T. Talme,

Article2019

Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review

K.J. Mason, S. Williams, Zenas Z N Yiu, Kathleen McElhone, Darren M. Ashcroft, C. Elise Kleyn, Zarif K. Jabbar‐Lopez, Caroline Owen, Nick J. Reynolds, Catherine Smith, Nina Wilson, Richard B. Warren, Christopher Em Griffiths

Article2008

Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.

Kristian Reich, Frank O. Nestlé, Ying Wu, Mohan Bala, D. Eisenberg, Cynthia Guzzo, Shu Li, Lisa T. Dooley, Christopher Em Griffiths